NORML

MARCH 23, 2020

For example, one recent CBD provider recently received warning letters from the US Food and Drug Administration and the Federal Trade Commission for improperly marketing the agent as a key component of its COVID-19 prevention package. A greater discussion of these cannabis safety guidelines are available from NORML here.). ”

CBD 345

CBD Therapy Treatment Packaging 345

Cannabis Law Report

JANUARY 31, 2022

Numinus Bioscience said that it is prepared to supply psilocybin in whole mushroom form, through three packaged doses equivalent to 10, 15, and 25mg of psilocybin. At this time, Numinus Bioscience said that it is prepared to supply psilocybin in whole mushroom form, through three packaged doses equivalent to 10, 15, and 25mg of psilocybin.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

Cannabis Law Report

SEPTEMBER 15, 2021

This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. Thus, historical use of cannabis cannot be relied upon in establishing a level of safety for these products in humans.

THC 105

THC Pets Events Hemp 105

Cannabis Law Report

JULY 30, 2019

In the 2018 issue of the INvisibleProject.org ‘s annual “ Medical Cannabis: One Therapy, Many Journeys ,” Ellen Lenox Smith believes it is imperative for society to understand the following fact about medical cannabis: “ it is an indigenous plant found in nature that is non-invasive and safe. Pain Foundation.

Marijuana 40

Marijuana Education Patients Research and Development 40

CannaMD

MAY 14, 2020

CannaMD has contacted Florida’s leading medical marijuana treatment centers (MMTCs) , who say they’re now just waiting on the Department of Health to issue rules regarding packaging and other essential requirements. Safety of production and packaging. Why Do People Like Marijuana Edibles?

Edibles 105

Edibles Marijuana THC Vaping 105

Puff Puff Post

NOVEMBER 5, 2019

Study #755-101-HV is a randomized, double-blind, vehicle-controlled, Phase 1 study designed to evaluate the local and systemic safety, tolerability, and pharmacokinetics of INM-755 cream applied daily on intact skin in healthy volunteers. Two strengths of INM-755 cream will be evaluated in 22 adult subjects over a 14-day treatment period.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Cannabis Law Report

OCTOBER 29, 2019

ElleVet Sciences is pleased to announce the results and publication of the first safety study on the use of hemp CBD/CBDA. The 12-week safety study, conducted by Dr. Joseph Wakshlag, DVM, Ph.D., This data gives us confidence in the use of both the chew and the oils as effective means for delivering CBD to your pet.”.

Safety 45

Safety CBD Clinical Trials Oil 45